Novavax Reports Second Quarter 2026 Financial Results and Operational Highlights

Novavax Reports Second Quarter 2026 Financial Results and Operational Highlights

* Reported total revenue of $57 million for the second quarter of 2026 and raised full-year 2026 Revenue Framework * Improved GAAP Combined R&D and SG&A expense guidance by $10 million at mid-point * Sanofi confirmed with Novavax that they are in advanced discussions with regulators regarding their Phase 3 COVID-19-Influenza Combination trial timing and intend to be among the first movers in the combination vaccine segment * Completion of manufacturing technology transfer to Sanofi expected in mid-2027 and would trigger a $75 million milestone payment to Novavax * Multiple partner-led experiments with Matrix-M are currently underway in a wide array of infectious disease and oncology targets * On track to advance C. difficile vaccine program into the clinic as early as 2027 GAITHERSBURG, Md., Aug. 6, 2026 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX) today announced its financial results and operational highlights for the second quarter ended June 30, 2026.